Scope and Claims Analysis for U.S. Patent 11,364,249 (Testosterone Undecanoate Oral Replacement Therapy)
Executive summary: U.S. Patent 11,364,249 claims a tightly bounded, performance-defined regimen for oral testosterone undecanoate replacement therapy in males with testosterone deficiency. Claim 1 anchors on (i) patient selection by morning serum testosterone <300 ng/dL, (ii) a specific twice-daily oral dosing regimen with food, (iii) a narrowly defined capsule-type composition (15–20 wt% testosterone undecanoate; polyoxyl vegetable oil 8–16 wt%; maize oil monoglycerides 63–68 wt%), (iv) a quantitative exposure target after steady state (Cave 300–1100 ng/dL and Cmax <2500 ng/dL), and (v) a dose adjustment loop based on measured steady-state serum levels. Dependent claims add specific carrier components (glyceryl monolinoleate, oleic acid, and “hydrophilic surfactant”) and tighter unit-dose embodiments (capsules containing ~225 mg testosterone undecanoate) plus pharmacokinetic constraints on Cmax/Cave (≤2.7) and dose-normalized Cave (>1.9×10^-6 dL^-1).
The result is a patent estate that is likely to be most infringed by label-adjacent and PK-tailored product concepts (oral TEU with matching excipients and an individualized dose schedule achieving those exposure ranges), rather than by any oral testosterone undecanoate product that only broadly “treats hypogonadism.”
What does U.S. Patent 11,364,249 claim for oral testosterone undecanoate replacement therapy?
Claim 1: core independent method claim scope
Claim 1 is the dominant scope driver. It is a method-of-treatment claim that combines:
-
Indication and patient selection
- “male having a condition associated with a deficiency or absence of endogenous testosterone”
- explicitly includes a screening criterion: morning serum testosterone <300 ng/dL
-
Dosing frequency, route, and meal condition
- “orally administering, twice a day with food”
- twice-daily administration is a structural limitation. “With food” is also a structural limitation.
-
Composition definition by wt% ranges and delivered daily dose
- pharmaceutical composition includes:
- testosterone undecanoate 15–20 wt%
- carrier:
- polyoxyl vegetable oil 8–16 wt%
- maize oil monoglycerides 63–68 wt%
- regimen provides about 450 mg testosterone undecanoate per day
- This ties the method to a particular formulation class and a particular delivered daily TEU amount.
-
Steady-state exposure monitoring and dose-adjustment loop
- “determining the serum level of testosterone … after administration … at steady state”
- then administering a “quantity … twice a day with food” based on the determined steady-state level
- This makes infringement turn on the presence of a monitor-and-adjust workflow, not just a fixed-dose regimen.
-
Therapeutic exposure target limitations
- the administered regimen is intended to yield:
- Cave in the range 300–1100 ng/dL
- Cmax <2500 ng/dL
- The “Cave” and “Cmax” constraints are quantitative performance requirements.
-
Additional constraint: dose quantity set by measured Cave
- “wherein said quantity is based on said determined serum level … at steady state”
- Even if initial dosing provides ~450 mg/day, claim language requires a specific later dosing quantity determined by measured steady-state levels to land in the Cave and Cmax constraints.
Practical inference for scope
- The claim is not satisfied by a regimen that merely treats “low testosterone” without demonstrating these PK targets.
- The claim is not satisfied by an oral TEU product with substantially different excipient composition if it falls outside the wt% ranges.
- The claim is not satisfied by once-daily dosing or dosing without food.
Dependent claims 2–5: carrier component expansions
- Claim 2: carrier further comprises glyceryl monolinoleate
- Claim 3: carrier further comprises oleic acid
- Claim 4: carrier further comprises a hydrophilic surfactant (and claim 1’s carrier context)
- Claim 5: reiterates hydrophilic surfactant where claim 3 context applies (oleic acid also present)
These dependent limits narrow infringement to formulations containing those added carrier elements, but they also create multiple “ways in” for an infringing product depending on composition.
Dependent claims 6–8: unit dosage embodiments
- Claim 6: at least one administration as 2 capsules, each about 225 mg TEU
- Claim 7: at least one administration as 1 capsule of about 225 mg TEU
- Claim 8: same as claim 7 but depending on claim 5 context
These introduce capsule-level embodiments consistent with twice-daily dosing by capsule count rather than only by total daily mg.
Dependent claims 9–12: exposure shape constraint (Cmax/Cave)
- Claim 9: single dose administration yields Cmax/Cave ≤ 2.7
- Claims 10–12: same ratio constraint for claims involving oleic acid (and hydrophilic surfactant dependency chain)
This further tightens the “PK profile” beyond the absolute thresholds in claim 1. Even if Cmax <2500 ng/dL and Cave in range, the product must also satisfy the ratio in the specified measurement context.
Dependent claims 13–14: dose-normalized Cave constraint
- Claim 13: single dose provides dose-normalized Cave > 1.9×10^-6 dL^-1
- Claim 14: same in oleic acid context
This is a second PK performance dimension tying exposure to dose-normalization, likely intended to ensure adequate systemic exposure per administered TEU amount.
How narrow is the formulation scope in U.S. Patent 11,364,249?
Key formulation elements in claim 1
The claimed composition is defined by wt% ranges for three items:
- Testosterone undecanoate: 15–20 wt%
- Polyoxyl vegetable oil: 8–16 wt%
- Maize oil monoglycerides: 63–68 wt%
These are not generic “lipid excipient” descriptors; they are concentration ranges. To fall outside literal scope, an accused product would need to materially depart from these wt% bands.
What is actually “claimed” vs. merely referenced?
- Claim 1 claims a method that includes administration of a pharmaceutical composition meeting the specified composition ranges and yielding about 450 mg TEU/day.
- Infringement is therefore a combination of:
- the composition (as defined),
- the administration method (twice daily, with food),
- the clinical workflow (measure steady-state serum, then adjust quantity),
- the PK targets (Cave range and Cmax ceiling),
- plus dependent constraints if asserted.
What patient population and lab thresholds are required?
Morning serum testosterone <300 ng/dL (screening)
Claim 1’s patient selection is explicit:
- “a male identified as having a morning serum testosterone level of less than 300 ng/dL”
This limits scope to a defined hypogonadism population by lab threshold. Clinically, this resembles androgen deficiency selection criteria rather than general testosterone therapy.
Replacement therapy for deficiency or absence of endogenous testosterone
Claim 1 also includes:
- “condition associated with deficiency or absence of endogenous testosterone”
This is broad enough to cover hypogonadism types, but the morning-test cutoff narrows claim coverage for method infringement.
How do the PK targets in claim 1 control infringement risk?
Absolute exposure targets
Claim 1 requires:
- Cave 300–1100 ng/dL
- Cmax <2500 ng/dL
These are likely to be the most litigated parameters because they can be tested through bioanalysis in a steady-state setting.
Timing and context
The PK targets are tied to:
- “after administration … at steady state”
and then subsequent dosing quantity “based on” those measured levels.
That means the method prescribes an approach that uses steady-state measurement to achieve the exposure targets. A defendant can attempt to avoid infringement by changing the workflow such that the dose is not “based on” measured steady-state serum levels to hit the Cave and Cmax constraints, even if the product conceptually produces similar PK.
What additional exposure constraints do dependent claims add (Cmax/Cave and dose-normalized Cave)?
Cmax/Cave ≤ 2.7 (ratio)
Claims 9–12 impose:
- single-dose Cmax/Cave ratio ≤ 2.7
This constrains the exposure “shape,” often reflecting formulation and food interaction properties. It is not the same as the Cmax ceiling; a product could have Cmax <2500 ng/dL but still exceed the ratio limit, or vice versa.
Dose-normalized Cave > 1.9×10^-6 dL^-1
Claims 13–14 require:
- single-dose exposure normalization exceeding 1.9×10^-6 dL^-1
This is a dose efficiency metric. It can be used to differentiate between formulations that reach similar absolute exposures at different dosing amounts.
What does the capsule dosing language imply for product embodiments?
225 mg TEU capsule concept
Claims 6–8 describe administrations in terms of capsule count:
- “2 capsules having about 225 mg testosterone undecanoate” for an administration occasion
- “1 capsule having about 225 mg testosterone undecanoate” for an administration occasion
This suggests the claimed regimen is compatible with a TEU capsule strength that totals to ~450 mg/day with twice-daily administration, aligning with claim 1’s “about 450 mg per day” anchor.
This is important because a defendant product with a different TEU per capsule (e.g., substantially different strength) could avoid those dependent claim limitations, even if claim 1 is still potentially asserted depending on dose and formulation.
How does the claim structure allocate infringement across different product variables?
What must match for literal infringement of claim 1
A would-be infringing regimen must align simultaneously with:
- Patient selection: morning testosterone <300 ng/dL
- Route and schedule: oral, twice daily, with food
- Formulation ranges: TEU 15–20 wt%; polyoxyl vegetable oil 8–16 wt%; maize oil monoglycerides 63–68 wt%
- Dose: about 450 mg/day TEU initially and dosing quantity adjusted later
- Monitoring: steady-state testosterone measurement
- PK outcomes: Cave 300–1100 ng/dL; Cmax <2500 ng/dL
Dependent claim infringement requires additional matches
- glyceryl monolinoleate, oleic acid, and hydrophilic surfactant
- capsule dosing embodiments at ~225 mg/capsule
- single-dose Cmax/Cave ≤ 2.7
- dose-normalized Cave > 1.9×10^-6 dL^-1
What does the patent landscape likely look like around U.S. 11,364,249 for oral testosterone undecanoate?
Litigation posture is likely framed around “method claims + PK outcomes”
Given the claim language, enforcement typically depends on demonstrating:
- the accused product’s formulation composition falls within wt% ranges, and
- the accused regimen in the real world (or in clinical trials) includes steady-state measurement and dose adjustment based on those results to reach the specified Cave and Cmax constraints.
This means the “landscape” around 11,364,249 is usually about:
- overlapping formulation patents (lipid systems, surfactants, solubilizers)
- overlapping clinical/PK patents (exposure targets, steady-state monitoring, individualized dosing)
- overlapping method-of-use patents (testosterone deficiency selection and replacement therapy)
Competitor scenario mapping (conceptual)
Without access to the complete claims set for related patents and the full prosecution history, a reliable landscape can still be characterized at a high level:
- If another oral TEU product uses a different lipid excipient system outside the wt% bands, it is weaker on claim 1 formulation matching, but could still be asserted on narrower dependent carrier components if those components are present.
- If a competitor follows a fixed-dose regimen without a steady-state measurement and dose adjustment protocol, it creates a potential design-around against claim 1’s “quantity based on determined steady-state level” limitation.
- If a competitor hits different exposure targets (Cave outside 300–1100 ng/dL or Cmax ≥2500 ng/dL), it avoids the PK constraints in claim 1 and likely avoids the tighter dependent PK constraints.
This is the practical enforcement logic embedded in the claims.
Key takeaway mapping: what variables are most important in an invalidity or infringement attack?
Infringement “hot spots”
- Evidence of twice-daily with food dosing
- Evidence of morning serum testosterone <300 ng/dL selection
- Evidence the administered product formulation meets wt% ranges
- Evidence of steady-state measurement and dose adjustment based on those results
- Measured Cave and Cmax at steady state meeting thresholds
- If dependent claims asserted: Cmax/Cave ≤2.7 and dose-normalized Cave >1.9×10^-6 dL^-1
- If dependent claims asserted: presence of glyceryl monolinoleate and/or oleic acid and/or hydrophilic surfactant
Validity “hot spots” (claim structure suggests typical arguments)
- Prior art that discloses similar lipid formulations and similar PK goals can challenge novelty, but claim 1’s combination of patient selection, dosing schedule with food, formulation wt% ranges, and specific PK targets creates a multi-element burden for novelty and obviousness.
- The most vulnerable elements are those that are broadly known in testosterone replacement regimens, but the combination with exact wt% ranges and PK thresholds can preserve patentability if the prior art does not teach the same integrated approach.
Key Takeaways
- U.S. Patent 11,364,249 is a method-of-treatment patent with tight formulation and PK performance constraints for oral testosterone undecanoate replacement therapy.
- Claim 1 requires: morning testosterone <300 ng/dL, oral twice daily with food, a specific excipient wt% composition (TEU 15–20%; polyoxyl vegetable oil 8–16%; maize oil monoglycerides 63–68%), ~450 mg/day, steady-state measurement, and dosing adjusted to achieve Cave 300–1100 ng/dL and Cmax <2500 ng/dL.
- Dependent claims narrow further by adding carrier components (glyceryl monolinoleate, oleic acid, hydrophilic surfactant), 225 mg/capsule embodiments, and additional single-dose PK constraints (Cmax/Cave ≤2.7 and dose-normalized Cave >1.9×10^-6 dL^-1).
- Enforcement risk is highest for products and real-world regimens that replicate the full integrated workflow (patient selection + steady-state monitoring + dose adjustment) and deliver the claimed PK targets using formulations within the specified excipient wt% ranges.
FAQs
- Does a fixed-dose oral testosterone undecanoate regimen infringe claim 1 if it achieves Cave and Cmax targets?
- How important are the wt% excipient ranges (polyoxyl vegetable oil; maize oil monoglycerides) to claim 1 infringement?
- Do the dependent claims on glyceryl monolinoleate and oleic acid create separate infringement “paths” if the base formulation matches claim 1?
- What lab timing is implied by “morning serum testosterone <300 ng/dL” for the claimed patient selection step?
- If single-dose Cmax/Cave exceeds 2.7, can claim 1 still be asserted based on steady-state Cave and Cmax targets?
References
No sources were provided in the prompt, and no patent/public record details (title, assignee, publication numbers, file history, related patents, prosecution dates, or jurisdictions) were supplied beyond the excerpted claim text. Therefore, no citations can be produced.
